Novo’s semaglutide franchise could hit $24B in 2023

Sales of Ozempic, Wegovy and Mounjaro rose to new heights in the second quarter. 

For 1H23, Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported nearly $9.2 billion in sales across the Ozempic, Rybelsus and Wegovy franchises. Based on growth rates from 2H22 to 1H23, the semaglutide franchise may be on pace for $24.3 billion in total sales in 2023, with obesity drug Wegovy contributing nearly $7.8 billion alone...